Allosteric mTOR inhibitors also have proven their efficacy in T-ALL cells when combined with other targeted therapeutics, which included inhibitors of NOTCH1 [125], MEK [111], Janus kinase 3 (Jak3) [111], Bcl-2 [126], and glycolysis [127]. This evidence concerns the gene JAK3 and acute lymphoblastic leukemia.